2ND ADVANCED COURSE ON THE PHARMACOLOGICAL TREATMENT OF DRUG RESISTANT EPILEPSIES (DRE): FROM RARE TO COMMON EPILEPSIES

Friday, 8th November
16:15 h - 16:30 h

Welcome and Introduction

Jose M Serratosa. Madrid
Manuel Toledo Argany. Barcelona
Torbjörn Tomson. Stockholm
Bernhard J Steinhoff. Kork
16:30 h - 17:00 h

Concept, epidemiology and social impact of DRE

Eugen Trinka. Salzburg
17:00 h - 17:30 h

Other impact of DRE: Mortality and SUDEP

Torbjörn Tomson. Stockholm
17:30 h - 18:00 h

Pseudo-DRE: Concept and diagnosis

Torbjörn Tomson. Stockholm
18:00 h - 19:00 h

Cases: Difficult to diagnose DRE

Chairman: Manuel Toledo Argany
Javier Salas Puig. Barcelona
Laura Abraira. Barcelona
Saturday, 9th November
08:30 h - 09:00 h

Basic mechanisms

Heidrun Potschka. Munich
09:00 h - 09:30 h

Can we predict DRE in the focal epilepsies?

Mar Carreño. Barcelona
09:30 h - 10:00 h

Pharmacokinetic interactions between ASMs used in polytherapy

Cecilie Johannessen Landmark. Oslo
10:00 h - 10:30 h

Rational polytherapy V.2024: Interactions of third generation ASMs

Andres M Kanner. Miami
10:30 h - 11:00 h

Break

11:00 h - 11:30 h

Overtreatment vs therapeutic nihilism

Bernhard J Steinhoff. Kork
11:30 h - 12:30 h

Cases: Polytherapy and interactions

Chairman: Manuel Toledo Argany
Javier Salas Puig. Barcelona
Laura Abraira. Barcelona
12:30 h - 13:00 h

Symposium 1: A whole-patient approach to specific DEEs management to consider more than seizure outcomes (Sponsored by Jazz Pharmaceuticals)

Chairman: Manuel Toledo Argany
Bernhard J Steinhoff. Kork
13:00 h - 14:00 h

Lunch

14:00 h - 14:30 h

ASMs close to launching and future strategies

Jacqueline French. New York
14:30 h - 15:00 h

Advanced therapies

Jose M Serratosa. Madrid
15:00 h - 15:30 h

How a patient lives DRE

Torie Robinson. London
15:30 h - 16:00 h

Break

16:00 h - 16:30 h

Drug resistant IGEs: Clinical characteristics

Javier Salas Puig. Barcelona
16:30 h - 17:00 h

Treatment of drug resistant IGEs

Guido Rubboli. Dianalund
17:00 h - 17:30 h

Symposium 2: Uncontrolled epilepsy: can we do better? (Sponsored by Angelini Pharma)

Chairman: Mar Carreño
Rhys Thomas. Newcastle
Sunday, 10th November
08:30 h - 09:00 h

Clinical characteristics of the main types of DEEs

Elena Gardella. Dianalund
09:00 h - 09:30 h

Treatment of Dravet disease, Lennox-Gastaut syndrome, and other DEEs

Elena Gardella. Dianalund
09:30 h - 10:30 h

Cases: DEEs

Chairman: Manuel Toledo Argany
Javier Salas Puig. Barcelona
Laura Abraira. Barcelona
10:30 h - 11:00 h

Break

11:00 h - 11:30 h

Symposium 3: Fenfluramine: Key Management Strategies to Maximize Efficacy (Sponsored by UCB Pharma)

Chairman: Jose M Serratosa Fernández
Patricia Smeyers. Valencia
11:30 h - 12:15 h

Outcome measures in DRE clinical trials

Jacqueline French. New York
12:15 h - 12:45 h

Comprehensive evaluation test

12:45 h - 13:00 h

Conclusions

Jose M Serratosa. Madrid
Manuel Toledo Argany. Barcelona
Torbjörn Tomson. Stockholm
Bernhard J Steinhoff. Kork